FORMULATION ARTICLES
-
![Future-GettyImages-834713748]( "Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions")
Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future DirectionsThis last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.
-
![Financial security, wealth protection, money insurance-GettyImages-2288391875]( "Protecting The Platform: Trade Secret Protection For RNA Biotech Companies")
Protecting The Platform: Trade Secret Protection For RNA Biotech CompaniesAs RNA therapeutics grow more complex and collaborative, trade secrets are becoming an increasingly important part of protecting valuable platform innovation.
-
![Measuring Success GettyImages-1319232417]( "How Should We Measure The True Potency Of RNA Therapeutics?")
How Should We Measure The True Potency Of RNA Therapeutics?An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.
-
![business model-GettyImages-879532512]( "From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery?")
From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery?We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies.
-
![Human Internal Organs Anatomy-GettyImages-1391174702]( "Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery")
Beyond GalNAc: Reengineering siRNA For Extrahepatic DeliveryWe discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.
-
![Asthma inhaler-GettyImages-2240010472]( "Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases")
Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic DiseasesTargeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.
FORMULATION VIDEOS
Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.
Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.
Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.
Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1264101698-lab-research-scientist]( "Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications")
Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.
-
![mRNA iStock-1295693748]( "Transfection Solutions For Highly Reliable And Effective Gene Silencing With siRNA And Co.")
We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.
-
![GettyImages-2160715091 lab analysis]( "Targeted LC-MS/MS Detection Of Lipid Impurities In Lipid Nanoparticles")
Learn about an HPLC-MS/MS method for detecting lipid impurities in lipid nanoparticles (LNPs) and why it is critical for quality control of LNP-based drug delivery systems.
-
![GettyImages-1182436133 scientist, lab, research, oncology]( "Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced Therapeutics")
Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced TherapeuticsPrecision in nanoparticle processing is key for drug delivery and vaccines. Learn how monodispersed formulations enhance reproducibility and stability for next-generation therapeutics, like RNA-LNPs.
-
![GettyImages-597935610 cell and gene]( "Delivering The Promise Of Gene Therapy")
Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.
-
![Cytiva-602047-2. Translation of RNA]( "Translation Of RNA Medicines From Design To Clinic")
Understand the advantages and challenges of lipid-based delivery systems for successful translation of RNA into clinical development.
-
![GettyImages-1194781834-cell]( "mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations")
Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.
